PURPOSE To compare pain-related treatment satisfaction, patient-perceived side effects,
functioning, and well-being in patients with advanced cancer who were receiving either …

Cancer patients requiring strong opioid analgesia (n= 202; mean age, 61.5 years; range, 18–
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …

A transdermal fentanyl patch for the treatment of chronic cancer-related pain is available in
four dosages (25, 50, 75, and 100 microg/hr). Fentanyl is released from a 72-hour reservoir …

Patients with moderate to severe malignancy-related pain frequently require the use of
opioid pharmacotherapy. Unfortunately, many cancer patients continue to be prescribed …

Transdermal fentanyl was released in Germany in 1995. From October 1996 to February
1998 transdermal treatment was documented for 1005 patients (506 men and 499 women …

To treat cancer pain, physicians often decide to jump directly from step 1 of the World Health
Organization (WHO) analgesic ladder to step 3. The use of transdermal fentanyl in patients …

Fentanyl is a synthetic opioid agonist which interacts primarily with the μ-opioid receptor.
The low molecular weight, high potency and lipid solubility of fentanyl make it suitable for …

Fentanyl has been incorporated into a transdermal therapeutic system (TTS) containing a
rate-limiting membrane that provides constant release of the opioid. TTS fentanyl provides …

Purpose: To evaluate effectiveness and safety information of transdermal fentanyl
(TDF)(Duragesic/Durogesic*) and sustained-release oral morphine (SRM) in cancer pain …

The long-term therapy of 51 patients using transdermal fentanyl was evaluated. The
transdermal therapy was performed for 158 days (range, 15–855 days). The need for …